相似文献
1
US FDA Advisory Committee meetings held to discuss isotretinoin, safety issues and a new accutane formulation.
Skin Therapy Lett. 2000;6(2):5.
2
A review of the European Directive for prescribing systemic isotretinoin for acne vulgaris.
J Eur Acad Dermatol Venereol. 2006 Aug;20(7):773-6. doi: 10.1111/j.1468-3083.2006.01671.x.
3
The cost of clear skin: balancing the social and safety costs of iPLEDGE with the efficacy of Accutane (isotretinoin).
Seton Hall Law Rev. 2007;37(2):625-60.
4
Safety issues in isotretinoin therapy.
Semin Cutan Med Surg. 2001 Sep;20(3):166-83. doi: 10.1053/sder.2001.28209.
5
Isotretinoin prescribing: finding a balance between benefit and risk.
Pharmacoepidemiol Drug Saf. 2005 Sep;14(9):611-3. doi: 10.1002/pds.1145.
6
Accutane (isotretinoin) and psychiatric adverse effects.
CMAJ. 2003 Jan 7;168(1):66.
7
Safety of a new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne: A randomized trial comparing micronized isotretinoin with standard isotretinoin.
J Am Acad Dermatol. 2001 Aug;45(2):196-207. doi: 10.1067/mjd.2001.115966.
8
Family physicians and accutane.
Am Fam Physician. 2000 Oct 15;62(8):1772, 1774, 1777.
9
Accutane risk management program strengthened.
FDA Consum. 2002 Jan-Feb;36(1):8.
10
Possible association between isotretinoin and inflammatory bowel disease.
Am J Gastroenterol. 2006 Jul;101(7):1569-73. doi: 10.1111/j.1572-0241.2006.00632.x.
Zotero 插件